PASCAL BIOSCIENCES ANNOUNCES CONTINUING DISCUSSIONS WITH SŌRSE TECHNOLOGY AND TESTING OF CANNABINOIDS FOR COVID-19 TREATMENT NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, BRITISH COLUMBIA, May 27, 2020 – Pascal Biosciences…
Read MoreNOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, March 10, 2020 (GLOBE NEWSWIRE) -- Pascal Biosciences Inc. (TSX.V: PAS) ("Pascal") is pleased to announce that it has entered into a…
Read MoreThe project will utilize Pascal’s proprietary antibodies & Y-Biologics’ novel bispecific antibody platform technology, ALiCE Vancouver, British Columbia, Seattle, Washington and Daejon, Korea, Oct. 29, 2019 — Pascal Biosciences Inc. (TSX.V:PAS) (“Pascal”) and Y-Biologics (together the “Companies”) today announced…
Read MoreVANCOUVER, BRITISH COLUMBIA, and SEATTLE, WASHINGTON, Sept 23, 2019 –Pascal Biosciences Inc. (TSX.V:PAS) (“Pascal” or the “Company”) today revealed the mechanism whereby cannabinoids may directly aid in cancer treatment. Specific cannabinoids identified by Pascal scientists enhance the immunogenicity of tumor…
Read MoreVANCOUVER, BRITISH COLUMBIA, and SEATTLE, WASHINGTON, Sept 11, 2019 –Pascal Biosciences Inc. (TSX.V:PAS) (“Pascal” or the “Company”). Pascal announces that Dr. Patrick Gray, CEO, will present an update today on the Company’s lead cannabinoid-based drug candidate, PAS-403, at the Second…
Read MoreVANCOUVER, BRITISH COLUMBIA, and SEATTLE, WASHINGTON, May 29, 2019 – Pascal Biosciences Inc. (TSX.V:PAS) (“Pascal” or the “Company”), a drug discovery and development company, today announced the company will present at the upcoming BIO International Convention taking place June 3-6…
Read MorePascal Biosciences Announces Formation of Clinical Advisory Board Preeminent Neuro-Oncology Experts to Guide PAS-403 Development Efforts VANCOUVER, BRITISH COLUMBIA, and SEATTLE, WASHINGTON, May 8, 2019 – Pascal Biosciences Inc. (TSX.V:PAS)(“Pascal” or the “Company”), a drug discovery and development company, today…
Read MoreVANCOUVER, BRITISH COLUMBIA, and SEATTLE, WASHINGTON, April 23, 2019 – Pascal Biosciences Inc. (TSX.V:PAS) (“Pascal” or the “Company”), a drug discovery and development company, today provided a corporate update for the first quarter of 2019. “We’ve made significant strides since…
Read MoreVANCOUVER, BRITISH COLUMBIA, and SEATTLE, WASHINGTON, April 1, 2019 – Pascal Biosciences Inc. (TSX.V:PAS) (“Pascal” or the “Company”), a drug discovery and development company, today announced that Carl Weissman has joined the company in the role of acting President. Weissman…
Read MoreVANCOUVER, BRITISH COLUMBIA, and SEATTLE, WASHINGTON, March 18, 2019 – Pascal Biosciences Inc. (TSX.V:PAS) (“Pascal” or the “Company”), a drug discovery and development company, today announced a partnership with Mitacs for a multi-year cancer research project at the University of…
Read More